Last reviewed · How we verify
Sorafenib+Pazopanib
Sorafenib and Pazopanib are multi-kinase inhibitors that target various pathways involved in tumor growth and angiogenesis.
Sorafenib and Pazopanib are multi-kinase inhibitors that target various pathways involved in tumor growth and angiogenesis. Used for Advanced renal cell carcinoma, Hepatocellular carcinoma.
At a glance
| Generic name | Sorafenib+Pazopanib |
|---|---|
| Sponsor | Technical University of Munich |
| Drug class | multi-kinase inhibitor |
| Target | RAF, VEGFR, PDGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Sorafenib and Pazopanib inhibit multiple kinases, including RAF, VEGFR, and PDGFR, which are involved in tumor growth, angiogenesis, and metastasis. This leads to a decrease in tumor size and a reduction in the formation of new blood vessels that supply the tumor.
Approved indications
- Advanced renal cell carcinoma
- Hepatocellular carcinoma
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Hand-foot skin reaction
- Rash
Key clinical trials
- Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment (PHASE2)
- TDM for Optimized Outcome in Patients With mRCC.
- A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
- Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan
- High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia (NA)
- Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer (PHASE2)
- Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sorafenib+Pazopanib CI brief — competitive landscape report
- Sorafenib+Pazopanib updates RSS · CI watch RSS
- Technical University of Munich portfolio CI